| Company News |
Therapeutic focus - Melanoma awaiting breakthrough but data approaching
(September 10, 2010)
|
Anti-Angiogenic Anti-Cancer Agent Avastin® Condition for Approval (All Patients Surveillance) Removed in Japan Chugai
(September 08, 2010)
|
Plexxikon Data Shows PLX4032 Selectivity Enables Substantial Pathway Inhibition and Significant Clinical Response Plexxikon
(September 07, 2010)
|
Roche Announces Operational Excellence initiative Roche
(September 03, 2010)
|
Event - Roche announces timely efficiency drive as Avastin decision looms
(September 03, 2010)
|
Anti-Cancer Agent, Xeloda® Filed for Advanced or Refractory Gastric Cancer By “New Drug Application Based on Evidence in the Public Domain” Chugai
(September 02, 2010)
|
6th Roche Commission Goes To Sofia Gubaidulina Roche
(August 27, 2010)
|
Genentech Receives Refuse to File Letter from FDA for T-DM1 ImmunoGen
(August 27, 2010)
|
Roche and ImmunoGen sent reeling by FDA roadblock
(August 27, 2010)
|
Roche Provides Update On FDA Application For T-DM1 Roche
(August 27, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
| Company Profile |
|
|
| Profile
|
Roche, a family controlled, Swiss healthcare company. Business segments include: Pharmaceuticals and Diagnostics.
16 APR 2009: Roche acquired Genentech on 26 MAR 2009. Within EvaluatePharma, Genentech is classified as an overlapping inactive company and its product sales (1986-2009) overlap with Roche.
Roche owns >50% of Chugai and consolidates 100% of the sales. |
| Listed or Private Company
|
Listed |
| Company Classification
|
Global Majors |
| Company Website
|
Website
|
|
Full Company Profile Information
| EventAnalyzer - Last Key Event |
|
| Closing Price DateClosing Price Date
|
EventAnalyzer Note
|
Market Cap (US $m)
|
Change (%)
|
Change (+$m)
|
| 7/26/2010 |
26 Jul: Collins Stewart states that a company presentation on 22 Jul provides little clarity on pipeline and restructuring issues. |
104,993 |
-1.1% |
-1,003 |
|
| Top 3 Products (Worldwide Sales 2007/08) |
|
|
| RX Sales Chart |
| Roche
|
Data
|
Growth
|
|
2007 |
2008 |
2008 |
| Revenues By Segment
|
| Pharmaceuticals
|
| Pharmaceuticals Sales (In-depth)
|
| Rx & OTC Pharmaceuticals
|
| Prescription (Rx) Pharmaceuticals9 |
30,66110 |
33,24711 |
|
+8% |
|
|
| Therapy Area Focus in 2008 |
| Roche
|
|
2008 |
| WW Rx & OTC Sales By Therapy Area
|
| Main Categories
|
| Blood |
1,573 |
| Cardiovascular |
375 |
| Central Nervous System12 |
99813 |
| Dermatology14 |
249 |
| Endocrine |
384 |
| Gastro-Intestinal |
700 |
| Musculoskeletal |
1,154 |
| Oncology & Immunomodulators |
20,77515 |
| Respiratory |
97616 |
| Sensory Organs |
875 |
| Systemic Anti-Infectives |
1,97417 |
| Other Rx & OTC Pharma |
3,21218 |
|
| EvaluatePharma® Coverage of Marketed and Pipeline Products |
|
|
Product Count
|
| Roche
19 |
520 |
|
|
|